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Background: Mistletoe (Viscum album L.) extracts are widely used in complementary cancer therapy. Aim of this
study was to evaluate safety and efficacy of a standardized mistletoe extract (abnobaVISCUMW Quercus, aVQ) in
patients with gastric cancer.
Patients and Methods: 32 operated gastric cancer patients (stage Ib or II) who were waiting for oral
chemotherapy with the 5-FU prodrug doxifluridine were randomized 1:1 to receive additional therapy with aVQ or
no additional therapy. aVQ was injected subcutaneously three times per week from postoperative day 7 to week 24
in increasing doses. EORTC QLQ-C30 and -STO22 Quality of Life questionnaire, differential blood count, liver
function tests, various cytokine levels (tumor necrosis factor (TNF)-alpha, interleukin (IL)-2), CD 16+/CD56+ and CD
19+ lymphocytes were analyzed at baseline and 8, 16 and 24 weeks later.
Results: Global health status (p <0.01), leukocyte- and eosinophil counts (p ≤0.01) increased significantly in the
treatment group compared to the control group. Diarrhea was less frequently reported (7% vs. 50%, p=0.014) in the
intervention group. There was no significant treatment effect on levels of TNF-alpha, IL-2, CD16+/CD56+ and CD 19+
lymphocytes and liver function tests measured by ANOVA.
Conclusion: Additional treatment with aVQ is safe and was associated with improved QoL of gastric cancer
patients. ClinicalTrials.Gov Registration number NCT01401075.
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Gastric cancer is the most frequent cancer in Korea and
the second most common cancer worldwide [1,2] Surgi-
cal resection remains the primary curative treatment op-
tion with overall 5-year survival rates of 15% to 35% [3].
The survival rate for patients with gastric cancer has only
slightly be improved in the last years by using technical
advances in surgery and adjuvant chemotherapy [4].
It is well known that surgical stress suppresses the
immune system. Granulocyte function, numbers of nat-
ural killer (NK) cells and T-helper lymphocytes decrease* Correspondence: roman.huber@uniklinik-freiburg.de
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reproduction in any medium, provided the orafter major surgery [5,6]. Furthermore, chemotherapeutics
like 5-FU frequently (≥1:100, <1:10) cause immunosup-
pression (neutropenia, myelosupression) with increased
risk of infection [7] and may have a negative impact on
patients´quality of life [8]. Adjuvant 5-FU as monotherapy
or in combination with other chemotherapies has been
effective in gastric cancer patients UICC stage I-IV to
reduce mortality [9] and is a standard therapy in patients
with gastric cancer stage II-III [10]. Instead of 5-FU in
Japan and Korea also the 5-FU prodrug doxifluridine
(5-DFUR), which can be applied orally, is used [11].
Aqueous mistletoe extracts (Viscum album L.) have
been widely used in complementary cancer therapy for
decades [12]. Mistletoe extracts as well as isolated
mistletoe-lectins were shown to have immunomodulatory. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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number and activity of immunological effector cells like
NK-cells [13,14] and T-lymphocytes [15]. NK-cell activity
can predict the prognosis of patients with gastric cancer
[16] and NK-cells are reduced stage dependently in
Korean gastric cancer patients [17] but there are not many
studies on this issue. NK-cells were, therefore, chosen as
an immunological parameter in this trial. Low Interleukin
(IL)-2 is regarded as disadvantageous for sufficient T-cell
response [18] and was, therefore, also included into the
analysis.
Moreover, mistletoe extracts inhibited tumor cell pro-
liferation and tumor growth in numerous in vitro studies
and animal experiments [19-22]. The effects could be
attributed to the specific components mistletoe lectin I–
III. [22,23]. abnobaVISCUMW Q (aVQ) is one of the
mistletoe preparations with the highest content of
mistletoe lectins on the market [24].
It has been shown in clinical trials, especially with
breast or colorectal cancer patients, that QoL improved
under mistletoe therapy [12,25]. In operated patients
with gastric cancer during chemotherapy, mistletoe
treatment has not yet been investigated [25]. We, there-
fore, conducted a randomized clinical trial to investigate
the effect on quality of life, immunomodulation and
safety of adjuvant subcutaneous mistletoe treatment on




32 patients, sixteen each for the treatment group and for
the control group, were recruited for this pilot trial from
March 2006 to April 2008. Inclusion criteria were: post-
operative gastric cancer (stage Ib or II) waiting for oralPatients screened: 42
Patients randomized: 32
Treatment group: 16 Control gro
Patients analyzed: 15 Patients an
Figure 1 Flow of the study.chemotherapy with the orally applied 5-FU prodrug and
intermediate metabolite of capecitabine doxifluridine
(5-DFUR), aged between 19 and 70 years, Eastern Coopera-
tive Oncology Group (ECOG) performance status 0 or 1,
normal liver function and renal function. Exclusion criteria
were: inability to answer the QoL scales, concomitant ther-
apy with steroids or biological response modifiers, individ-
ual hypersensitivity to mistletoe preparations, pregnancy or
lactating and participation in another clinical trial.
The protocol was approved by the Institutional Review
Board of ASAN Medical Center (irbreview@amc.seoul.
kr). Written informed consent was obtained from all
patients. The flow of the study is shown in Figure 1.
Study design
The study was prospective, controlled and randomized,
comparing two arms. Patients were allocated on the
basis of unstratified block randomization (block size: 4)
to the intervention group (aVQ) or no additional therapy
(control group) according to a randomization list.
Randomization was concealed, as allocation was gener-
ated by a computer program and not known before to
the study personnel. Blinding with a placebo-injection in
the control group was not possible because subcutane-
ous injections with mistletoe preparations result in local
reactions at the injection site which deblind patients and
the physician [26].
Primary outcome parameter was Quality of Life improve-
ment during the 4 visits. aVQ was injected subcutaneously
three times a week from postoperative day 7 to week 24
with increasing doses (8 injections 0.02 mg followed by 8
injections 0.2 mg, 8 injections 2mg and 8 injections 20mg
and then continued with 20mg to the end of the study).
This schedule corresponds to the recommended treatment
schedule of the manufacturer.up: 16
alyzed: 14
Screening failures: 10
Drop outs and reasons:
1 (Treatment) / 2 (Control)
(all withdrawal of informed 
consent)
Kim et al. BMC Complementary and Alternative Medicine 2012, 12:172 Page 3 of 7
http://www.biomedcentral.com/1472-6882/12/172The 5-fluorouracil prodrug 5-DFUR is approved to
treat gastric cancer in Japan and Korea and is used as
adjuvant treatment in a dose of 600–900 mg per day, de-
pending on the weight of the patient. Chemotherapy
started together with the mistletoe treatment one week
after operation.
The QoL (EORTC QLQ-C30 and -STO22 question-
naires), liver function tests, peripheral differential blood
count, adverse events and immunological parameters
(levels of TNF-alpha, IL-2, CD16+/CD56+ and CD 19+
lymphocytes) were recorded at each visit (baseline, week
8, 16 and 24). The immunological parameters were ana-
lyzed in the quality controlled, accredited laboratory
Seoul Clinical Laboratories with established methods.
Medication
AbnobaVISCUMW Q 20 mg is an injectable, endotoxin-
free plant extract from the European mistletoe species
Viscum album L. for the treatment of malignant
tumors, tumor recurrences, and defined precanceroses.
AbnobaVISCUMW Q 20 mg (1 ampoule a 1 ml) con-
tains about 8500 ng/ml natural mistletoe lectins. The
mistletoe lectin content of the diluted preparations is
accordingly. 5-DFUR is used in Korea for adjuvant
therapy of gastric cancer in early stages and is an oral
prodrug of 5-FU.
Planned number of cases and statistical analysis
As this was a pilot study, 16 patients per group have been
planned. The independent t-test and repeated measured
ANOVA were used for statistical analysis and P-values less
than 0.05 (two-sided) were regarded as statistically signifi-
cant. Statistical analysis was performed using SPSS version
12.0 (Chicago, Illinois, USA).
Results
A total of 32 patients with stage Ib/II gastric cancer, eli-
gible for adjuvant oral doxifluridine treatment, wereTable 1 Demographic and pathologic data (SD= standard de
patients in
Treatment group
Stage Ib 15 (1)
Stage II 1
Total gastrectomy 4
Distal gastrectomy 12 (1)
Sex (M:F) 13 (2):3
Age (year, mean ± SD, median) 53.75±10.25, 54
BMI (mean ± SD) 23.21±2.09
Systolic BP (mmHg, mean ± SD) 112.88±9.23
Diastolic BP (mmHg, mean ± SD) 70.75±7.69
Pulse rates (mean ± SD) 73.06±12.89enrolled into this clinical trial. Three of the enrolled
patients, one from the treatment group and two from
the control group, were drop outs because they retrieved
the informed consent.
No significant differences were observed in age, sex,
height, weight, blood pressure, pulse rate, type of oper-
ation (total gastrectomy or distal gastrectomy) and
pathologic classifications between the two groups
(Table 1). In both groups, the number of male patients
was significantly higher. There were 28 patients in stage
Ib and only one patient in stage II.
Except 3 QoL parameters (pain, p = 0.038; eating
restrictions, p = 0.037; hair loss, p = 0.023) and baso-
philes (p = 0.0315) baseline of QoL, immunological
parameters, hematology and liver function tests were
not different between the groups (Tables 2, 3, 4, 5).
Repeated analysis of variance (ANOVA) of the qual-
ity of life scales QLQ-C30 and QLQ-STO22 revealed a
strong improvement of the “Global Health Status”
(p = 0.0098) in the intervention group (Table 2). The
Global Health Status is a sum parameter of 2 ques-
tions of the QLQ-C30 questionnaire with a broader
range (range = 6) than the other 28 questions (range =
3), which allows a more precise judgment of the
patients situation regarding the overall health and
quality of life status. All other function and symptom
scales of the QLQ-C30 and the stomach cancer mod-
ule QLQ-STO22 did not show a significant effect of
the intervention. The analysis of variance for the
hematologic variables showed significantly higher
WBC counts (p = 0.0101) and eosinophil counts (p =
0.0036) in the intervention group. For the immuno-
logic variables repeated measured ANOVA detected
no significant differences in CD16+/CD56+ and CD
19+ lymphocytes, TNF-alpha and IL-2 between control
group and intervention group (Table 3). Anyhow, the
IL-2 mean values are considerably higher in the treat-












Table 2 QoL-Questionnaires: difference between treatment group (aVQ) and control group by independent t-test and
result of the repeated measured analysis of variance (ANOVA, influence of treatment)
Values at baseline (SD) Difference between aVQ and control
aVQ Control t t t t F
baseline week 8 week 16 week 24 ANOVA
Global health status 43.75 (12.73) 38.33 (22.45) −0.8192 −0.7853 −4.3243** −2.2335* 7.7133**
Function scales QLQ-C30 Physical Function 60.83 (18.52) 59.11 (18.66) −0.2577 0.7034 −1.1736 −0.4788 0.2499
Role Function 61.46 (35.34) 54.44 (30.52) −0.5925 0.9454 −1.616 −0.5529 0.4646
Emotional Function 60.94 (21.02) 55.56 (28.64) −0.5933 0.2221 2.2619* 0.0475 0.0851
Cognitive Function 75.00 (21.94) 77.78 (15.00) 0.4137 1.209 1.5594 −0.2262 1.0832
Social Function 58.33 (29.81) 58.89 (35.56) 0.047 −0.684 0.7015 −0.396 0.0107
Symptom scales QLQ-C30 Fatigue 44.44 (17.68) 48.89 (27.47) 0.5317 −0.1426 −0.4653 0.3975 0.0812
Nausea &Vomiting 17.71 (18.73) 5.56 (13.61) −2.0761 −0.764 −1.1565 0.102 2.6182
Pain 51.04 (21.49) 55.56 (33.73) 0.4411 −0.9279 −0.2941 0.6467 0.0258
Dyspnoea 25.00 (28.54) 33.33 (35.63) 0.7157 0.4233 −1.1535 −0.5658 0.0023
Insomnia 37.50 (29.50) 53.33 (37.37) 1.3036 −1.2579 0.130 −0.8726 0.0214
Appetite loss 33.33 (27.22) 37.78 (35.34) 0.3905 0.6096 −0.2297 0.7067 0.4156
Constipation 31.11 (34.43) 22.22 (27.22) −0.7845 −0.1521 −0.5357 −0.7574 0.7652
Diarrhea 22.22 (24.12) 15.56 (24.77) −0.7467 −0.6185 −2.6407* −1.0367 3.606
Financial difficulties 37.50 (34.16) 28.89 (27.79) −0.772 −0.0922 −1.6535 −0.8739 1.0459
Symptoms QLQ-STO22 Dysphagia 34.03 (22.76) 46.67 (21.50) 1.5901 −0.1442 1.0202 0.4126 1.7228
Pain 43.75 (26.44) 63.89 (25.13) 2.1742* 0.757 −0.7438 0.3681 1.9013
Reflux symptom 27.08 (15.70) 22.22 (23.76) −0.6676 −1.2596 −1.7927 −1.0456 3.1538
Eating restriction 29.17 (22.57) 46.11 (20.62) 2.1843* 0.2106 0.7307 0.1629 2.3484
Anxiety 42.36 (23.38) 40.00 (28.73) −0.25 −1.5867 −0.0319 0.4544 0.2471
Single items QLQ-STO22 Having a dry mouth 39.58 (30.35) 57.78 (36.66) 1.4998 −1.0582 −1.1941 −1.3797 0.1782
Taste 22.92 (23.47) 40.00 (31.37) 1.708 −0.4383 0.7737 0.6099 1.4529
Body image 41.67 (28.54) 33.33 (30.86) −0.7791 −2.3885* −0.0962 0.00 1.4123
Hair loss 20.00 (18.26) 83.33 (33.33) 3.4125* 0.5143 0.4672 −1.4018 1.4885
*p<0.05, **p<0.01, SD: standard deviation.
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for the IL-2 values a significant difference results (F =
4.4794; p = 0.0433). Also the IL-2 median at visit 3,
but not at the other visits, was significantly higher in
the intervention group compared to the control group
(Table 4, p=0.034, two sided Mann-Withney U-test).Table 3 Immunological parameters: difference between treat
t-test and result of the repeated measured analysis of varianc
Values at baseline (SD)
aVQ Control t
baseline
CD 16+/CD 56+ 10.5 (4.16) 9.38 (3.61) −0.816
CD 19+ 21.06 (13.71) 20.25 (8.97) −0.198
TNF-α 2.18 (1.61) 1.6 (0.49) −1.381
IL-2 1.04 (0.56) 0.94 (0.44) −0.58
SD: standard deviation; CD 16+/CD 56+ : lymphocytes with CD 16+/CD 56+ (NK-cells
interleukin-2.Mean alkaline phosphatase (ALK) values were higher
in the in the treatment group (visit 2, 3, 4, Table 5). Any-
how, a significant influence of the mistletoe treatment
on the ALK values could not be confirmed by ANOVA
(F = 2.6545, p = 0.1145). Increase of ALK is a known
side-effect of doxifluridine therapy.ment group (aVQ) and control group by independent
e (ANOVA, influence of treatment)
Difference between aVQ and control
t t t F
week 8 week 16 week 24 ANOVA
−0.3458 −0.452 −0.2512 0.2823
0.2786 0.1885 0.3131 0.0199
−1.4135 −0.407 −1.6893 2.7911
−1.0269 −1.34 −1.019 2.1181
), CD 19+ : lymphocytes with CD 19+, TNF-α: tumor necrosis factor alpha, IL-2:
Table 4 IL-2 mean values and standard deviation (SD): difference between treatment group (aVQ) and control group of
the 4 visits by independent t-test
IL-2 concentration in pg/ml (mean, (SD), median) t-test
aVQ Control t p
Baseline 1.04 (0.56) 0.89 0.94 (0.44) 0.85 −0.5804 0.5662
Visit 2 59.08 (219.95) 0.93 0.76 (0.52) 0.56 −1.0269 0.3219
Visit 3 243.46 (702.12) 0.75 0.55 (0.42) 0.42 −1.3399 0.2016
Visit 4 70.84 (267.49) 0.81 0.46 (0.38) 0.75 −1.0190 0.3255
IL-2: interleukin-2.
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control group (n = 96) and the treatment group (n =
92). Except 2 serious adverse events (SAE’s), 1 case of
post-operative bleeding and 1 case of an acute infec-
tion, both in the treatment group and 1 AE with severe
degree (itching at injection site, treatment group) all
AE´s were mild or moderate. The SAE’s were judged as
not related to the study medication. In the treatment
group 26 of the 92 adverse events had at least a pos-
sible relationship to the mistletoe treatment. 80% (21
cases) of them were related to reactions at the injection
site like local pain, itching, rash or urticaria. The others
were 1 case of chest pain, 1 case of myalgia, 1 case of
dizziness and 1 case of diarrhea. In the control group
20 cases of diarrhea (21% of the 96 cases) were
recorded. The difference in diarrhea (6.7% in the treat-
ment group, 50% in the control group, p = 0.014) was
statistically significant. All recorded cases of diarrhea
had a mild degree but in 3 patients of the control
group the symptoms persisted until the end of the
study.Table 5 Routine laboratory parameters: mean difference and
and control group by independent t-test and result of the rep
of treatment)
Values at baseline (SD)
aVQ Control t
at baseline
WBCx1000/μl 6.21 (2.13) 5.24 (1.17) −1.595
Platelets x1000/μl 61.38 (77.07) 72.19 (83.77) 0.38
Neutrophils % 64.65 (8) 63.66 (8.29) −0.345
Lymphocytes % 21.83 (6.37) 22.94 (7.51) 0.4493
Monocytes % 7.07 (2.91) 7.74 (3.69) 0.5746
Eosinophils % 6.08 (3.89) 4.91 (2.39) −1.028
Basophiles % 0.37 (0.21) 0.76 (0.63) 2.3308*
Protein g/dl 6.16 (0.44) 6.31 (0.37) 1.0894
AST U/l+ 19.62 (4.26) 21 (8.48) 0.5798
ALT U/l† 19.44 (9.39) 20.31 (11.27) 0.2386
ALK U/l‡ 65.75 (16.43) 72.56 (48.02) 0.5369
Bilirubin mg/dl 0.84 (0.24) 0.79 (0.28) −0.471
+AST: aspartate aminotransferase; †ALT: alanine aminotransferase; ‡ ALK: alkaline phDiscussion
While the effect of treatment with mistletoe prepara-
tions on survival of cancer patients is still unclear be-
cause adequate studies are lacking, there is an increasing
number of studies showing beneficial effects regarding
QoL [12,25]. Our controlled, randomized pilot study is
in line with these findings, showing that also in patients
with gastric cancer during adjuvant oral chemotherapy
treatment with a mistletoe extract significantly improved
the global health status (p<0.01). Interestingly, except
the lower frequency of diarrhea, no specific improve-
ment during mistletoe treatment occurred (Table 2).
Possible mechanisms how mistletoe treatment could im-
prove the global health status include immunological
effects and elevating body temperature [27], because im-
munological disturbances and an altered circadian
rhythm are factors that may contribute to reduced QoL
in cancer patients [28].
White blood cell count and eosinophils increased in the
treatment group compared to the control group. These
effects have been reported in other studies evaluatingstandard deviation (SD) between treatment group (aVQ)
eated measured analysis of variance (ANOVA, influence
Difference between aVQ and control
t t t F
at week 8 at week 16 at week 24 ANOVA
−2.1951* −2.0243 −2.1076* 7.614*
−0.5491 0.2193 0.3207 0.0442
−0.7475 1.6094 −0.291 0.0055
2.1109* −0.068 1.0294 1.5019
0.5052 0.2823 0.8871 0.776
−3.677** −3.2466** −2.3029* 10.1286**
0.4129 0.0282 −0.081 2.0996
0.1437 0.3964 1.0308 0.4806
0.4339 1.0689 0.4566 0.6618
0.064 1.3147 −0.0086 0.2651
−2.146* −3.0221** −2.8479** 2.6545
−0.1546 −0.4448 −0.6975 0.2735
osphatase; *p<0.05 **p<0.01.
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toe lectins in healthy probands and are most likely related
to a stimulation of GM-CSF, IL-5 and IFN-gamma by
mistletoe lectin [15,29]. The increase in eosinophils and
WBC might therefore also in our study with cancer
patients be related to a stimulation of IL-5 and/or GM-CSF
Apart from WBC and eosinophils there were no significant
differences in immune parameters between the groups.
IL-2 function seems to contribute considerably to the
operation-induced immunosuppression in gastric cancer
patients [30] and preoperative treatment with IL-2 had
been promising [31,32]. Applying a non-parametric statis-
tical method (rank transformation) the IL-2 values signifi-
cantly increased in the group of gastric cancer patients
receiving mistletoe treatment. This can, however, be
explained by outliers. Peak levels were measured 7 times
only in the treatment group and not in the control group.
Analysis of medians showed significantly higher values at
visit 3 in the intervention group. Anyhow, the IL-2 in-
crease might have been missed in ANOVA analysis due to
the low number of patients or might have been compro-
mised by the concurrent chemotherapy. To distinguish
this effect certainly a much larger number of patients
would be necessary. Nevertheless it can be assumed that
the increased WBC and eosinophil count and possibly also
the strong IL-2 increase in individual patients are a result
of the immunomodulatory effect of the mistletoe extract.
The compliance regarding administration of the
mistletoe extract was good. There was no drop-out
related to the investigated medication. The tolerability
and safety of the medication were also good. Mistletoe
treatment related local reactions at the injection site did
not lead to a discontinuation of treatment. With the
exception of local reactions, there were no significant
differences concerning number of adverse events or la-
boratory parameters between the intervention group
and the control group. Moreover, in the intervention
group, diarrhea was less frequently reported than in
the control group (7% versus 50%, p=0.014). Reduced
diarrhea has also been reported in a non-interventional
trial when abnobaVISCUM was given in parallel to ad-
juvant chemotherapy in breast cancer patients [33].
Mucosal injury is a relevant side effect of modern anti-
neoplastic therapies caused by cytotoxicity, apoptosis
induction and anti-angiogenesis [34] and is typical for
FU-based chemotherapies [35]. The beneficial effect of
the mistletoe therapy on diarrhea could possibly be
explained by its immunomodulating properties which
might have inhibited apoptosis in the normal gut mu-
cosa. This needs, however, further investigations.
Conclusions
In this pilot trial the mistletoe extract was safe, improved
the global health status and reduced the rate of diarrheain gastric cancer patients receiving adjuvant oral
chemotherapy.
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